Rituximab and Canakinumab Use During Lactation: No Detectable Serum Levels in Breastfed Infants.

Bosshard, Nicole; Zbinden, Astrid; Eriksson, Klara Kristin; Förger, Frauke (2021). Rituximab and Canakinumab Use During Lactation: No Detectable Serum Levels in Breastfed Infants. Rheumatology and therapy, 8(2), pp. 1043-1048. Springer 10.1007/s40744-021-00313-z

[img]
Preview
Text
FFOE2.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (229kB) | Preview

INTRODUCTION

In breastfeeding patients with chronic inflammatory rheumatic diseases, a postpartum flare may require the use of biologics. However, data on the safety of biologics during lactation are scarce, potentially impeding the decision-making process.

CASE SERIES

We report two cases of women in whom treatment with a monoclonal IgG antibody (rituximab or canakinumab) was indicated during the lactation period. In both cases, breastfeeding was continued, and drug levels in the mother's serum, in serial breast milk samples and in the infant's serum were measured. Both rituximab and canakinumab showed minimal drug concentrations in breast milk and no detectable levels in the infants' sera.

CONCLUSION

The lack of detectable levels of rituximab and canakinumab in the sera of breastfed infants reflects the poor oral bioavailability of these biologics and helps to promote their use in breastfeeding patients.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology and Immunology

UniBE Contributor:

Eriksson, Klara Kristin, Förger, Frauke

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2198-6576

Publisher:

Springer

Language:

English

Submitter:

Brigitte Isenschmid

Date Deposited:

03 Dec 2021 17:21

Last Modified:

05 Dec 2022 15:55

Publisher DOI:

10.1007/s40744-021-00313-z

PubMed ID:

33999372

Uncontrolled Keywords:

Canakinumab Lactation Rituximab

BORIS DOI:

10.48350/161852

URI:

https://boris.unibe.ch/id/eprint/161852

Actions (login required)

Edit item Edit item
Provide Feedback